Afatinib [65], marketed as Gilotrif, among other names, is an aniline-quinazoline derivative and part of the tyrosine kinase inhibitor family, typically administered orally for treating specific NSCLC cases with EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.